Literature DB >> 8602185

Cost-effectiveness analysis in a setting of budget constraints--is it equitable?

P A Ubel1, M L DeKay, J Baron, D A Asch.   

Abstract

BACKGROUND: One of the promises of cost-effective analysis is that it can demonstrate how to maximize health benefits attainable within a specific limited budget. Many people argue, however, that when there are budget limitations, the use of cost-effectiveness analysis leads to health care policies that are inequitable.
METHODS: We asked prospective jurors, medical ethicists, and experts in medical decision making to choose between two screening tests for a population at low risk for colon cancer. One test was more cost effective than the other but because of budget constraints was too expensive to be given to everyone in the population. With the use of the more effective test for only half the population, 1100 lives could be saved at the same cost as that of saving 1000 lives with the use of the less effective test for the entire population.
RESULTS: Fifty-six percent of the prospective jurors, 53 percent of the medical ethicists, and 41 percent of the experts in medical decision making recommended offering the less effective screening test to everyone, even though 100 more lives would have been saved by offering the more expensive test to only a portion of the population. Most of the study participants justified this recommendation on the basis of equity. A smaller number stated either that it was not politically feasible to offer a test to only half the population or that the additional benefit of the more expensive test (100 more lives saved) was too small to justify offering it to only a portion of the public.
CONCLUSIONS: People place greater importance on equity than is reflected by cost-effectiveness analysis. Even many experts in medical decision making -- those often responsible for conducting cost-effectiveness analyses -- expressed discomfort with some of its implications. Basing health care priorities on cost effectiveness may not be possible without incorporating explicit considerations of equity into cost-effectiveness analyses or the process used to develop health care policies on the basis of such analyses.

Entities:  

Keywords:  Empirical Approach; Health Care and Public Health; Medicaid

Mesh:

Year:  1996        PMID: 8602185     DOI: 10.1056/NEJM199605023341807

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

Review 1.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

2.  Ethical implications in the allocation of scarce medical resources in Poland.

Authors:  T Tolloczko
Journal:  Sci Eng Ethics       Date:  2000-01       Impact factor: 3.525

3.  The HAART side of resource allocation.

Authors:  Pedram Sendi; Amiram Gafni
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

4.  Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.

Authors:  Anders Anell
Journal:  Eur J Health Econ       Date:  2004-02

Review 5.  The ethics and reality of rationing in medicine.

Authors:  Leslie P Scheunemann; Douglas B White
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

6.  The challenge of commissioning for populations.

Authors:  Andrew Lee; Fiona Head; Chris Packham; Mike Robinson
Journal:  Br J Gen Pract       Date:  2012-05       Impact factor: 5.386

7.  Public views on priority setting for high cost medications in public hospitals in Australia.

Authors:  Gisselle Gallego; Susan J Taylor; Paul McNeill; Jo-anne E Brien
Journal:  Health Expect       Date:  2007-09       Impact factor: 3.377

8.  On pharmacogenomics and cost-effectiveness analysis at the individual level.

Authors:  Mohan V Bala; Gary A Zarkin
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 9.  Prognosis without treatment as a modifier in health economic assessments.

Authors:  Ross Camidge; Andrew Walker; James J Oliver; Fiona Nussey; Simon Maxwell; Duncan Jodrell; David J Webb
Journal:  BMJ       Date:  2005-06-11

10.  Clinical ethical dilemmas: convergent and divergent views of two scholarly communities.

Authors:  A M Stiggelbout; A S Elstein; B Molewijk; W Otten; J Kievit
Journal:  J Med Ethics       Date:  2006-07       Impact factor: 2.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.